CRVS News and Press, Corvus Pharmaceuticals Inc. From 03/10/22

BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. ...

BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update ...

Gainers: Brookdale Senior Living BKD +16%. American Shared Hospital Services AMS +12%. ImmunityBio IBRX +12%. I-Mab (NASDAQ:IMAB) +11%. Corvus Pharmaceuticals (NASDAQ:CRVS) +9%. Losers: Larimar Therapeutics LRMR -65%. Omnicell (NASDAQ:OMCL) -18%. M...

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its P...

BURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of a...

Today, we look at Corvus Pharmaceuticals, a company that has multiple candidates in development. The stock has had a roller coaster ride so far in 2021. A full investment analysis is presented in the paragraphs below. For further details see: Checking In On Corvus Pharma...

Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...

Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy Corvus enrolling additional patients with these cancers in a Phase 1b/2 trial, with additional data ant...

BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021. The Company will con...

BURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Mee...